Lilly leads the way with 4 entries, while Pfizer, AbbVie and GSK are also well represented.

In terms of therapeutic areas, we see a notable diversification away from oncology, with CNS (Alzheimer's, Parkinson's, MDD) and I&I (atopic dermatitis, ulcerative colitis, plaque psoriasis and alopecia) leading the way.

Most of these drugs have a wide band of sales estimates, so it's likely several will surprise in both directions.

Note: not exhaustive for all anticipated approvals